Study Results From Zika Virus Infected Mice Treated With BCX4430 to be Presented at WHO Conference

Edit Stockhouse 07 Mar 2016
RESEARCH TRIANGLE PARK, N.C., March 07, 2016 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc ... HHSN272201300017C.   ... BCX4430 is an RNA dependent-RNA polymerase inhibitor that has demonstrated broad-spectrum activity in vitro against more than 20 RNA viruses in nine different families, including filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses ... About BioCryst Pharmaceuticals ... ....

Study Results From Zika Virus Infected Mice Treated With BCX4430 to be Presented at WHO Conference (BioCryst Pharmaceuticals Inc)

Edit Public Technologies 07 Mar 2016
(Source. BioCryst Pharmaceuticals Inc) RESEARCH TRIANGLE PARK, N.C., March 07, 2016 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc ... HHSN272201300017C ... BCX4430 is an RNA dependent-RNA polymerase inhibitor that has demonstrated broad-spectrum activity in vitro against more than 20 RNA viruses in nine different families, including filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses....

BioCryst Awarded BCX4430 Advanced Development Contract (BioCryst Pharmaceuticals Inc)

Edit noodls 31 Mar 2015
(Source. BioCryst Pharmaceuticals Inc). BioCryst Awarded BCX4430 Advanced Development Contract ... administration of BCX4430 in healthy volunteers ... About BCX4430. BCX4430 is an RNA dependent-RNA polymerase inhibitor that has demonstrated broad-spectrum activity in vitro against more than 20 RNA viruses in nine different families, including filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses....

BioCryst Announces Study Results for BCX4430 in a Non-Human Primate Model of Ebola Virus Infection

Edit Stockhouse 23 Dec 2014
RESEARCH TRIANGLE PARK, N.C., Dec. 23, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc ... BCX4430 is an RNA dependent-RNA polymerase inhibitor that has demonstrated broad-spectrum activity in vitro against more than 20 RNA viruses in nine different families, including filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses. BioCryst is developing BCX4430 in collaboration with U.S....

BioCryst Announces Study Results for BCX4430 in a Non-Human Primate Model of Ebola Virus Infection (BioCryst Pharmaceuticals Inc)

Edit noodls 23 Dec 2014
(Source. BioCryst Pharmaceuticals Inc) ... RESEARCH TRIANGLE PARK, N.C., Dec ...    ... BCX4430 is an RNA dependent-RNA polymerase inhibitor that has demonstrated broad-spectrum activity in vitro against more than 20 RNA viruses in nine different families, including filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses. BioCryst is developing BCX4430 in collaboration with U.S ... BCRXW....

BioCryst Announces Initiation of a Phase 1 Clinical Trial of BCX4430 for the Treatment of ...

Edit Stockhouse 15 Dec 2014
RESEARCH TRIANGLE PARK, N.C., Dec. 15, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc ... injection in healthy subjects ... HHSN272201300017C. About BCX4430. BCX4430 is an RNA dependent-RNA polymerase inhibitor that has demonstrated broad-spectrum activity in vitro against more than 20 RNA viruses in nine different families, including filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses ... ....

BioCryst Announces Initiation of a Phase 1 Clinical Trial of BCX4430 for the Treatment of Hemorrhagic Fever Viruses (BioCryst Pharmaceuticals Inc)

Edit noodls 15 Dec 2014
(Source. BioCryst Pharmaceuticals Inc). BioCryst Announces Initiation of a Phase 1 Clinical Trial of BCX4430 for the Treatment of Hemorrhagic Fever Viruses ... BCX4430 is an RNA dependent-RNA polymerase inhibitor that has demonstrated broad-spectrum activity in vitro against more than 20 RNA viruses in nine different families, including filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses....

BioCryst Receives Additional NIAID Funding for Manufacture and Development of BCX4430 to Treat Hemorrhagic Virus Diseases (BioCryst Pharmaceuticals Inc)

Edit noodls 18 Sep 2014
... BSAV compound is BCX4430, an RNA dependent-RNA polymerase inhibitor that has demonstrated broad-spectrum activity against more than 20 RNA viruses in nine different families, including filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses. BioCryst is developing BCX4430 in collaboration with U.S....

BioCryst Participates in World Health Organization Consultation on Potential Ebola Therapies

Edit Stockhouse 04 Sep 2014
... BSAV compound is BCX4430, an RNA dependent-RNA polymerase inhibitor that has demonstrated broad-spectrum activity against more than 20 RNA viruses in nine different families, including filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses. BioCryst is developing BCX4430 in collaboration with U.S....

BioCryst Participates in World Health Organization Consultation on Potential Ebola Therapies (BioCryst Pharmaceuticals Inc)

Edit noodls 04 Sep 2014
... BSAV compound is BCX4430, an RNA dependent-RNA polymerase inhibitor that has demonstrated broad-spectrum activity against more than 20 RNA viruses in nine different families, including filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses. BioCryst is developing BCX4430 in collaboration with U.S....

BioCryst Receives Additional NIAID Funding to Conduct a Non-Human Primate Study of BCX4430 in Ebola ...

Edit Stockhouse 29 Aug 2014
... BSAV compound is BCX4430, an RNA dependent-RNA polymerase inhibitor that has demonstrated broad-spectrum activity against more than 20 RNA viruses in nine different families, including filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses. BioCryst is developing BCX4430 in collaboration with U.S....

BioCryst Receives Additional NIAID Funding to Conduct a Non-Human Primate Study of BCX4430 in Ebola Virus Disease (BioCryst Pharmaceuticals Inc)

Edit noodls 29 Aug 2014
... BSAV compound is BCX4430, an RNA dependent-RNA polymerase inhibitor that has demonstrated broad-spectrum activity against more than 20 RNA viruses in nine different families, including filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses. BioCryst is developing BCX4430 in collaboration with U.S....

BioCryst Receives Additional NIAID Funding to Advance Development of BCX4430 to Treat Hemorrhagic Fever Virus Diseases

Edit Stockhouse 13 Aug 2014
... BSAV compound is BCX4430, an RNA dependent-RNA polymerase inhibitor that has demonstrated broad-spectrum activity against more than 20 RNA viruses in nine different families, including filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses. BioCryst is developing BCX4430 in collaboration with U.S....
×